NIFTY  10,020.55  -0.00%
  SENSEX  32,383.30  0.00%
 CURRENCY  Rs  64.37/$ 75.57/€, 84.55/£
  GOLD  28,505.00  0.43%
  SILVER  38,535.00  1.17%
  DAX  12,305.11  0.33%
  FTSE  7,452.32  0.24%
  CAC  5,190.17  0.45%
  HANG SENG  27,131.17  0.71%
  NIKKEI  20,079.64  0.15%
  Shanghai Composite  3,249.78  0.03%
  DOW JONES  21,711.01  0.45%
  NASDAQ  6,422.75  0.16%
  S&P 500  2,477.83  0.03%
BIOCON Q1 : Consol PAT Rs 81.3 Cr Vs Rs 166 Cr, Down 51% YoY BIOCON Q1 : Consol Revenue From Ops Rs 933 Cr Vs Rs 992 Cr, Down 6% YoY KIRAN MAZUMDAR SHAW : Biologics Business Had A Strong Quarter Led By Insulin Sales KIRAN MAZUMDAR SHAW : Q1 Financial Performance Muted Due To Weak $, GST Impact, Malaysia Ops Cost KIRAN MAZUMDAR SHAW : Major Milestone In Q1 Was USFDA Nod For Biosimilar Trastuzumab KIRAN MAZUMDAR SHAW : Also Received Indian Regulator's Approval For Biosimilar Bevacizumab KIRAN MAZUMDAR SHAW : Outlook For FY18 Remains Cautious KIRAN MAZUMDAR SHAW : Outlook On FY18 Depends On Approvals & Tender Outcomes For Biosimilars KIRAN MAZUMDAR SHAW : Anticipate GST Impact To Roll-Over Into Q2FY18 KIRAN MAZUMDAR SHAW : Expect GST Impact To Normalise By H1 2018 End